Annals of Surgical Oncology最新文献

Background: The association between tumor-infiltrating lymphocytes and tumor immunity has long been recognized. Among T-cell types, CD45RO-positive memory T cells (CD45RO⁺) are reported to correlate with survival in several cancer types, but clinical evidence is lacking in esophageal squamous cell carcinoma (ESCC).

Methods: In surgical specimens from 162 preoperatively untreated patients, immunohistochemistry for CD45RO was performed to evaluate the density of CD45RO⁺ in the tumor core (CT) and invasive margin (IM) using an auto-count method. Patients were classified into high- versus low-CD45RO⁺ groups based on CD45RO⁺ density in CT and IM separately and combined. The relationship between CD45RO⁺ density and clinicopathological factors, including prognosis, was evaluated.

Results: Average CD45RO⁺ density was 133/mm² in CT and 372/mm² in IM. No significant differences in clinicopathological factors according to high- versus low-CD45RO⁺ scores were identified. Using CT scores, the CD45RO⁺-high group had a better 5-year overall survival (OS) rate (77.2% vs. 54.7% CD45RO⁺-low, P = 0.0433), but OS rates did not differ statistically between the two groups by IM scores (75.7% vs. 50.3%, P = 0.0576). Using immunohistochemical scores for CT+IM, the survival difference was significant, with a 5-year OS rate of 73.7% for the CD45RO⁺-high group versus 46.3% for the CD45RO⁺-low group (P = 0.0141). Multivariate analysis identified CD45RO⁺ CT+IM density as an independent prognostic variable in OS (hazard ratio 2.27, 95% confidence interval 1.43-3.62, P = 0.0006).

Conclusions: Density of CD45RO⁺ expression in the CT and IM might be a predictor of long-term survival in ESCC.

Introduction: The standard of care for gastric cancer in the United States involves perioperative chemotherapy. While most post-therapy pathologic staging results are concordant (i.e. ypT⁺N⁺ or ypT0N0), patients occasionally display discordant results, such as ypT0N1. Herein, we characterized the survival of patients with ypT0N1 staging to better determine their categorization within the American Joint committee on Cancer (AJCC) staging system.

Methods: Using the National Cancer Database (NCDB), we queried all patients diagnosed with gastric adenocarcinoma from 2004 to 2021 who received neoadjuvant chemotherapy. Patients were stratified by their ypTNM stage: (1) ypT0N0; (2) ypT+N0; (3) ypT+N1; and (4) ypT0N1. Multivariable Cox proportional hazard regression was used to assess 5- and 10-year survival between ypTNM stages.

Results: A total of 28,985 patients received neoadjuvant chemotherapy, of whom 2378 (8.2%) had ypT0N0, 9402 (32.4%) had ypT+N0, 5339 (18.4%) had ypT+N1, and 318 (1.1%) had ypT0N1 staging. Overall, patients had a median age of 64 years, with the majority being male (74.9%) or White (82.2%). Additionally, 50.2% received care from an academic center, and 53.3% received neoadjuvant chemotherapy and radiotherapy. On multivariable analysis, patients with ypT0N1 had a 105% higher risk for mortality within 5 years (adjusted hazards ratio [aHR] 2.05, 95% confidence interval [CI] 1.69-2.50) and 86% increased risk within 10 years (aHR 1.86, 95% CI 1.54-2.23) when compared with ypT0N0.

Conclusion: Patients with stage ypT0N1 disease have worse 5- and 10-year outcomes than those with node-negative disease. Thus, their survival pattern most closely matches patients with ypstage IIB and III disease.

Background: Gallbladder cancer is a rare disease with poor prognosis, for which surgical resection is considered the only curative treatment.¹ The widespread adoption of laparoscopic cholecystectomy for benign biliary diseases has led to an increased incidence of postoperatively diagnosed gallbladder cancer.^2-5 Several studies have proposed that tumors exceeding stage T2 require additional resection.^3,6,7 However, reoperation for postoperatively diagnosed gallbladder cancer is technically difficult due to inflammatory adhesion or fibrosis around the hepatoduodenal ligament and gallbladder bed.^8,9 For such reasons, there are limited evidence regarding the safety and feasibility of laparoscopic reoperation and no clear indications for when to perform minimally invasive surgery.

Methods: In this multimedia article, we present the laparoscopic reoperation techniques for postoperatively diagnosed gallbladder cancer. We focus specifically on various approaches to surgically manage the cystic duct stump, depending on the length of remnant stump, degree of surrounding fibrosis, and margin status.

Results: We represent three cases with different approaches. In the first case, a patient with a long remnant stump is managed with clip ligation and resection of the stump. Second, a patient with a short remnant stump and severe fibrosis is treated with stump excision and suture closure. Lastly, bile duct resection is performed for a patient with margin involvement during the initial operation.

Conclusions: Various technical options exist to approach the remnant cystic duct stump during laparoscopic reoperation for postoperatively diagnosed gallbladder cancer.

Background: Perioperative complication rates and in-hospital mortality after radical nephroureterectomy (RNU) in patients with a history of heart valve replacement are unknown.

Methods: Within the National Inpatient Sample (2000-2019), we identified non-metastatic upper urinary tract carcinoma patients treated with RNU according to the presence or absence of a history of heart valve replacement. Propensity score matching (1:10 ratio) and multivariable logistic regression as well as Poisson regression models were used.

Results: Of 15,423 RNU patients, 151 (1.0%) harbored heart valve replacement. This proportion increased over the study span from 0.5% to 1.4% (p = 0.02). Heart valve replacement patients were older (median 78 vs. 72 years; p < 0.001), more frequently male (73 vs. 60%; p = 0.002), and more frequently harbored a Charlson Comorbidity Index (CCI) ≥3 (36 vs. 27%; p = 0.002). After 1:10 propensity score matching for age, sex, and CCI, the patients exhibited higher rates of perioperative bleeding (7.4 vs. 2.4%; odds ratio [OR] 3.2; p < 0.001), blood transfusions (24.0 vs. 17.0%; OR 1.6; p = 0.02), and cardiac complications (24.0 vs. 14.0%; OR 2.1; p < 0.001). Conversely, heart valve replacement patients did not exhibit higher rates of critical care therapy (OR 1.06; p = 0.8), higher rates of in-hospital mortality (OR 0.8; p = 0.8), and longer length of stay (OR 1.4; p = 0.052) than their RNU counterparts without a history of heart valve replacement.

Conclusion: RNU patients with a history of heart valve replacement are at significantly increased risk of perioperative bleeding, blood transfusions, and cardiac complications; however, despite these increased risks, they neither exhibited higher critical care therapy rates or higher in-hospital mortality rates, nor did they require significantly longer hospital stay.

Background: Surgery has recently been introduced into the multimodal management of patients with locally advanced pancreatic adenocarcinomas (LAPCs) thanks to the major pathological response seen with the advent of the multiagent regimen FOLFIRINOX. Distal pancreatectomy with celiac axis resection (DP-CAR) may be complicated by ischemic liver and gastric events.^1,2 Common hepatic artery reconstruction may prevent the occurrence of ischemic complications and can be an alternative to preoperative embolization of the celiac trunk.³ METHODS: The patient was a 65-year-old with LAPC of the pancreatic body, with infiltration of the celiac trunk, the splenoportal venous confluence, and the Treitz angle. Preoperative induction chemotherapy with FOLFIRNOX was administered over 12 cycles, resulting in radiological stability and normal carbohydrate antigen (CA) 19-9 levels. Positron emission tomography showed isolated activity of the tumor without distant metastasis. A DP-CARV procedure was performed, and a single saphenous graft was used to reconstruct the common hepatic artery and to create a venous patch to repair the venous confluence. The angle of the Treitz, along with the third and fourth duodenum, were resected and a duodenojejunal anastomosis on the second duodenal portion was performed. The left gastric artery was not reconstructed.

Results: Postoperative course was favorable but was complicated by a hematoma of the right groin necessitating evacuation. Pathology showed a pT4N2R0 pancreatic adenocarcinoma. The postoperative computed tomography scan showed no collection and patency of reconstructed vessels. Six months later, the patient is alive and disease-free, with patent reconstructed vessels.

Conclusions: Common hepatic artery reconstruction during DP-CAR represents a safe surgical option to reduce ischemic events related to celiac trunk resection, particularly in the FOLFIRINOX era. This technique integrated the surgical armamentarium of surgeons dealing with LAPC.

Objectives: This study aimed to develop and externally validate a model for predicting insufficient future liver remnant (FLR) hypertrophy after portal vein embolization (PVE) based on clinical factors and radiomics of pretreatment computed tomography (CT) PATIENTS AND METHODS: Clinical information and CT scans of 241 consecutive patients from three Swedish centers were retrospectively collected. One center (120 patients) was applied for model development, and the other two (59 and 62 patients) as test cohorts. Logistic regression analysis was adopted for clinical model development. A FLR radiomics signature was constructed from the CT images using the support vector machine. A model combining clinical factors and FLR radiomics signature was developed. Area under the curve (AUC) was adopted for predictive performance evaluation RESULTS: Three independent clinical factors were identified for model construction: pretreatment standardized FLR (odds ratio (OR): 1.12, 95% confidence interval (CI): 1.04-1.20), alanine transaminase (ALT) level (OR: 0.98, 95% CI: 0.97-0.99), and PVE material (OR: 0.27, 95% CI: 0.08-0.87). This clinical model showed an AUC of 0.75, 0.71, and 0.68 in the three cohorts, respectively. A total of 833 radiomics features were extracted, and after feature dimension reduction, 16 features were selected for FLR radiomics signature construction. When adding it to the clinical model, the AUC of the combined model increased to 0.80, 0.76, and 0.72, respectively. However, the increase was not significant.

Conclusions: Pretreatment CT radiomics showed added value to the clinical model for predicting FLR hypertrophy following PVE. Although not reaching statistically significant, the evolving radiomics holds a potential to supplement traditional predictors of FLR hypertrophy.